董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Heyward R. Donigan | -- | Director | -- | 未披露 | 未持股 | 2018-02-16 |
| James J. Peters | -- | Director | -- | 未披露 | 未持股 | 2018-02-16 |
| Craig W. Moore | 男 | Director | 81 | 17.78万美元 | 未持股 | 2018-02-16 |
| Jeffrey H. Burbank | 男 | Chief Executive Officer and Director | 55 | 273.08万美元 | 未持股 | 2018-02-16 |
| Daniel A. Giannini | 男 | Director | 75 | 18.60万美元 | 未持股 | 2018-02-16 |
| Reid S. Perper | 男 | Director | 65 | 18.10万美元 | 未持股 | 2018-02-16 |
| Earl R. Lewis | 男 | Director | 81 | 17.17万美元 | 未持股 | 2018-02-16 |
| Robert G. Funari | 男 | Chairman of the Board of Director | 77 | 22.29万美元 | 未持股 | 2018-02-16 |
| Jean K. Mixer | 女 | Director | 58 | 18.17万美元 | 未持股 | 2018-02-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey H. Burbank | 男 | Chief Executive Officer and Director | 55 | 273.08万美元 | 未持股 | 2018-02-16 |
| Winifred L. Swan | 女 | Senior Vice President and General Counsel | 53 | 89.87万美元 | 未持股 | 2018-02-16 |
| Joseph E. Turk, Jr. | 男 | President | 50 | 137.18万美元 | 未持股 | 2018-02-16 |
| Matthew W. Towse | 男 | Senior Vice President, Chief Financial Officer and Treasurer | 55 | 101.22万美元 | 未持股 | 2018-02-16 |
董事简历
中英对照 | 中文 | 英文- Heyward R. Donigan
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- James J. Peters
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Craig W. Moore
-
Craig W. Moore， 2009年12月进入公司董事会，2012年1月任董事长。2002年至今，Moore先生担任NxStage NXTM公司董事，薪酬委员会主席及审核委员会成员直至2013年7月。从1986年至2001年，Moore先生担任珠峰医疗保健服务公司董事局主席兼首席执行官，该公司是透析和合同服务的供应商。自2001年以来Moore先生相继担任一系列医疗保健服务业公司的顾问。同时Moore先生还担任“美国医院特供/巴克斯特医疗保健”公司管理层长达13年之久，主管销售，市场以及商业开发。从1992年直到2006年，Moore先生担任生物系统公司（BLSC）的董事，同时Moore先生还兼任多家私人公司董事。Moore先生是我们的独立董事之一。
Craig W. Moore was appointed to our Board of Directors in December 2009 and as Chairman of our Board of Directors in January 2012. Mr. Moore has served as director of NxStage Medical, Inc. NXTM since 2002 and currently serves as chairman of their Compensation Committee and was a member of their Audit Committee from 2003 to 2012. From 1986 to 2001 Mr. Moore was Chairman of the Board of Directors and Chief Executive Officer at Everest Healthcare Services Corporation, a provider of dialysis and contract services. Since 2001 Mr. Moore has acted as a consultant to various companies in the healthcare services industry. Mr. Moore also spent 13 years with American Hospital Supply/Baxter Healthcare, where Mr. Moore held senior management positions in sales, marketing and business development. Mr. Moore served as a director of Biologic System Corporation (BLSC) from 1992 through 2006. Mr. Moore also serves as a director on several private company boards. Mr. Moore holds a B.A. in Business from Adrian College. - Craig W. Moore， 2009年12月进入公司董事会，2012年1月任董事长。2002年至今，Moore先生担任NxStage NXTM公司董事，薪酬委员会主席及审核委员会成员直至2013年7月。从1986年至2001年，Moore先生担任珠峰医疗保健服务公司董事局主席兼首席执行官，该公司是透析和合同服务的供应商。自2001年以来Moore先生相继担任一系列医疗保健服务业公司的顾问。同时Moore先生还担任“美国医院特供/巴克斯特医疗保健”公司管理层长达13年之久，主管销售，市场以及商业开发。从1992年直到2006年，Moore先生担任生物系统公司（BLSC）的董事，同时Moore先生还兼任多家私人公司董事。Moore先生是我们的独立董事之一。
- Craig W. Moore was appointed to our Board of Directors in December 2009 and as Chairman of our Board of Directors in January 2012. Mr. Moore has served as director of NxStage Medical, Inc. NXTM since 2002 and currently serves as chairman of their Compensation Committee and was a member of their Audit Committee from 2003 to 2012. From 1986 to 2001 Mr. Moore was Chairman of the Board of Directors and Chief Executive Officer at Everest Healthcare Services Corporation, a provider of dialysis and contract services. Since 2001 Mr. Moore has acted as a consultant to various companies in the healthcare services industry. Mr. Moore also spent 13 years with American Hospital Supply/Baxter Healthcare, where Mr. Moore held senior management positions in sales, marketing and business development. Mr. Moore served as a director of Biologic System Corporation (BLSC) from 1992 through 2006. Mr. Moore also serves as a director on several private company boards. Mr. Moore holds a B.A. in Business from Adrian College.
- Jeffrey H. Burbank
-
Jeffrey H. Burbank，他在1998年创立了NxStage，并担任董事及首席执行官。他在公司发展，营销和为终末期肾脏疾病患者制造产品等方面拥有超过25年的的深入管理经验。自NxStage成立以来，他领导公司经历其所有的发展阶段，包括成功启动，商业活动的快速增长，首次公开募股，以及收购Medisystems Corporation。在建立NxStage之前，他联合创立了Vasca（该公司提供创新性的植入式接入设备），并担任总裁，首席执行官，以及公司董事会主席。他在Gambro（一家医疗技术公司）工作了9年，获得了重要的行业经验。他在Gambro最后的职位是营销和高级技术总监。
Jeffrey H. Burbank is Chief Executive Officer and a member of Board of Directors and has served in these positions since he founded the company in December 1998. Mr. Burbank has over 30 years of in-depth management experience with companies developing, marketing and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Mr. Burbank co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received his BS in Industrial Engineering from Lehigh University. - Jeffrey H. Burbank，他在1998年创立了NxStage，并担任董事及首席执行官。他在公司发展，营销和为终末期肾脏疾病患者制造产品等方面拥有超过25年的的深入管理经验。自NxStage成立以来，他领导公司经历其所有的发展阶段，包括成功启动，商业活动的快速增长，首次公开募股，以及收购Medisystems Corporation。在建立NxStage之前，他联合创立了Vasca（该公司提供创新性的植入式接入设备），并担任总裁，首席执行官，以及公司董事会主席。他在Gambro（一家医疗技术公司）工作了9年，获得了重要的行业经验。他在Gambro最后的职位是营销和高级技术总监。
- Jeffrey H. Burbank is Chief Executive Officer and a member of Board of Directors and has served in these positions since he founded the company in December 1998. Mr. Burbank has over 30 years of in-depth management experience with companies developing, marketing and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Mr. Burbank co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received his BS in Industrial Engineering from Lehigh University.
- Daniel A. Giannini
-
Daniel A. Giannini，他自2005年担任NxStage的董事，目前担任本公司的审计委员会主席。他还担任多家私人和非营利公司董事会董事。在PricewaterhouseCoopers（一家审计及专业服务公司）作为一名注册会计师工作超过30年之后，他于2005年退休。在PricewaterhouseCoopers最后的五年里，他担任审计合伙人，并领导公司亚特兰大办事处的技术，信息，通信和娱乐业务。
Daniel A. Giannini has served as a director of NxStage since 2005 and currently serves as Chair of our Audit Committee. He has also served as a director on several private and non-profit company boards. Mr. Giannini retired in 2005 after a more than 30-year career as a Certified Public Accountant with PricewaterhouseCoopers LLP, an auditing and professional services firm. During his last five years at PricewaterhouseCoopers, Mr. Giannini served as an audit partner and led the Technology, Information, Communications and Entertainment practice at the firm’s Atlanta office. - Daniel A. Giannini，他自2005年担任NxStage的董事，目前担任本公司的审计委员会主席。他还担任多家私人和非营利公司董事会董事。在PricewaterhouseCoopers（一家审计及专业服务公司）作为一名注册会计师工作超过30年之后，他于2005年退休。在PricewaterhouseCoopers最后的五年里，他担任审计合伙人，并领导公司亚特兰大办事处的技术，信息，通信和娱乐业务。
- Daniel A. Giannini has served as a director of NxStage since 2005 and currently serves as Chair of our Audit Committee. He has also served as a director on several private and non-profit company boards. Mr. Giannini retired in 2005 after a more than 30-year career as a Certified Public Accountant with PricewaterhouseCoopers LLP, an auditing and professional services firm. During his last five years at PricewaterhouseCoopers, Mr. Giannini served as an audit partner and led the Technology, Information, Communications and Entertainment practice at the firm’s Atlanta office.
- Reid S. Perper
-
Reid S. Perper，他自2005年担任NxStage的董事。自2011年5月，他担任Health Evolution Partners（一家专注于医疗保健的私募股权投资公司）的高级顾问，支持其在欧洲地区的投资。从2008年到2013年，他是MCT Advisors（一家总部设在伦敦的金融咨询公司）的创始人和合伙人。从2004年到2009年，他担任Healthcare Investment Partners（一家专注于医疗保健的私募股权投资公司）的董事总经理。从2000年到2003年，他担任CSFB Private Equity（一家私募股权投资管理公司）欧洲地区的董事总经理以及联席主管。在加入CSFB Private Equity之前，他担任DLJ Merchant Banking Partners（一家私募股权投资公司）的总经理。他在1988年加入投资银行Donaldson, Lufkin & Jenrette。从2004年到2005年，他还曾担任Caxton Europe Asset Management（一家投资管理公司）的投资专家。
Reid S. Perper has served as a director of NxStage since 2005 and currently serves as a member of both our Audit and Nominating and Corporate Governance Committees. Since May 2011 Mr. Perper has been a Senior Advisor supporting European investments with Health Evolution Partners, a healthcare focused private equity firm. From 2008 to 2013 Mr. Perper was a founder and partner of MCT Advisors LLP, a London based financial advisory firm. From 2004 to 2009 Mr. Perper was Managing Director of Healthcare Investment Partners LLC, a healthcare focused private equity firm. From 2000 to 2003 Mr. Perper was co-Head of European Private Equity at Credit Suisse and Managing Director of DLJ Merchant Banking Partners, both private equity firms. Mr. Perper joined the investment banking firm Donaldson, Lufkin & Jenrette in 1988 and was a founding member of DLJ Merchant Banking Partners, the firm’s private equity group. Mr. Perper also served as an investment professional for the investment management firm Caxton Europe Asset Management Ltd. from 2004 to 2005. - Reid S. Perper，他自2005年担任NxStage的董事。自2011年5月，他担任Health Evolution Partners（一家专注于医疗保健的私募股权投资公司）的高级顾问，支持其在欧洲地区的投资。从2008年到2013年，他是MCT Advisors（一家总部设在伦敦的金融咨询公司）的创始人和合伙人。从2004年到2009年，他担任Healthcare Investment Partners（一家专注于医疗保健的私募股权投资公司）的董事总经理。从2000年到2003年，他担任CSFB Private Equity（一家私募股权投资管理公司）欧洲地区的董事总经理以及联席主管。在加入CSFB Private Equity之前，他担任DLJ Merchant Banking Partners（一家私募股权投资公司）的总经理。他在1988年加入投资银行Donaldson, Lufkin & Jenrette。从2004年到2005年，他还曾担任Caxton Europe Asset Management（一家投资管理公司）的投资专家。
- Reid S. Perper has served as a director of NxStage since 2005 and currently serves as a member of both our Audit and Nominating and Corporate Governance Committees. Since May 2011 Mr. Perper has been a Senior Advisor supporting European investments with Health Evolution Partners, a healthcare focused private equity firm. From 2008 to 2013 Mr. Perper was a founder and partner of MCT Advisors LLP, a London based financial advisory firm. From 2004 to 2009 Mr. Perper was Managing Director of Healthcare Investment Partners LLC, a healthcare focused private equity firm. From 2000 to 2003 Mr. Perper was co-Head of European Private Equity at Credit Suisse and Managing Director of DLJ Merchant Banking Partners, both private equity firms. Mr. Perper joined the investment banking firm Donaldson, Lufkin & Jenrette in 1988 and was a founding member of DLJ Merchant Banking Partners, the firm’s private equity group. Mr. Perper also served as an investment professional for the investment management firm Caxton Europe Asset Management Ltd. from 2004 to 2005.
- Earl R. Lewis
-
Earl R. Lewis，从2000十一月起担任董事长，总裁和首席执行官；他在2013退休时担任总裁和首席执行官。他继续担任着董事长。他最初是由于Thermo Instrument Systems对Spectra Physics AB 的收购，在1999六月当选为董事。加盟FLIR之前，他曾在Thermo Instrument Systems担任多个职务，最近的职务是总裁和首席执行官。他是 Harvard BioScience和NxStage Medical的董事会成员，还是克拉克森大学和新汉普顿中学的理事。他获得了克拉克森技术学院学士学位，参加过布法罗大学，东北大学和哈佛大学的研究生课程。他获得了美国企业董事学院硕士专业董事认证，这是从事企业董事教育和认证的公共组织。
Earl R. Lewis served as Chairman, President and Chief Executive Officer of the Company from November 2000 until his retirement in May 2013 as President and Chief Executive Officer. He continues to serve as Chairman of the Board. Mr. Lewis was initially elected to the Board in June 1999 in connection with the acquisition of Spectra Physics AB which at the time owned approximately 35 of the Company by Thermo Instrument Systems, Inc. Prior to joining FLIR, Mr. Lewis served in various capacities at Thermo Instrument Systems, Inc., with his last role as President and Chief Executive Officer. Mr. Lewis is a member of the Board of Directors of Harvard BioScience and NxStage Medical, Inc. Mr. Lewis is a Trustee of Clarkson University and New Hampton School. Mr. Lewis holds a B.S. from Clarkson College of Technology and has attended post-graduate programs at the University of Buffalo, Northeastern University and Harvard University. Mr. Lewis holds a Masters Professional Director Certification from the American College of Corporate Directors, a public company director education and credentialing organization. - Earl R. Lewis，从2000十一月起担任董事长，总裁和首席执行官；他在2013退休时担任总裁和首席执行官。他继续担任着董事长。他最初是由于Thermo Instrument Systems对Spectra Physics AB 的收购，在1999六月当选为董事。加盟FLIR之前，他曾在Thermo Instrument Systems担任多个职务，最近的职务是总裁和首席执行官。他是 Harvard BioScience和NxStage Medical的董事会成员，还是克拉克森大学和新汉普顿中学的理事。他获得了克拉克森技术学院学士学位，参加过布法罗大学，东北大学和哈佛大学的研究生课程。他获得了美国企业董事学院硕士专业董事认证，这是从事企业董事教育和认证的公共组织。
- Earl R. Lewis served as Chairman, President and Chief Executive Officer of the Company from November 2000 until his retirement in May 2013 as President and Chief Executive Officer. He continues to serve as Chairman of the Board. Mr. Lewis was initially elected to the Board in June 1999 in connection with the acquisition of Spectra Physics AB which at the time owned approximately 35 of the Company by Thermo Instrument Systems, Inc. Prior to joining FLIR, Mr. Lewis served in various capacities at Thermo Instrument Systems, Inc., with his last role as President and Chief Executive Officer. Mr. Lewis is a member of the Board of Directors of Harvard BioScience and NxStage Medical, Inc. Mr. Lewis is a Trustee of Clarkson University and New Hampton School. Mr. Lewis holds a B.S. from Clarkson College of Technology and has attended post-graduate programs at the University of Buffalo, Northeastern University and Harvard University. Mr. Lewis holds a Masters Professional Director Certification from the American College of Corporate Directors, a public company director education and credentialing organization.
- Robert G. Funari
-
Robert G. Funari，他自2013年1月担任NxStage的董事，目前担任本公司的董事长，以及提名和公司治理委员会主席。他自2004年担任Crescent Healthcare（在备用站点设置综合性制药和护理解决方案供应商）的首席执行官兼董事会主席，直到该公司于2012年2月被Walgreens收购。在加入Crescent Healthcare之前，1993年至1996年，他在Syncor International Corporation（一家公开上市的放射性药物服务公司）担任执行副总裁兼首席营运官，并从1996年到2003年，担任该公司的总裁兼首席执行官。他曾担任McKesson药物公司（一家药品，医疗用品和医疗信息技术提供商）的执行副总裁兼总经理，并曾在Baxter International（ 一家医疗保健公司）工作了超过18年，担任过多个领导职位。他曾是Beckman Coulter（一家诊断和生命科学公司）的董事，并从2005年至2011年12月担任其薪酬委员会的成员。他还曾是Pope and Talbot（一家林产品公司）的董事，并从2001年至2008年，担任其治理和薪酬委员会的成员。2004年至2008年，他曾担任First Consulting Group的董事。从1994年至2010年9月，他还担任过Bay Cities National Bank的董事，并从2007年到2010年9月，担任其董事长。他目前是一些非营利和私营公司的董事会成员，并且是RAND Healthcare Board of Advisors的成员。
Robert G. Funari has been a director of NxStage since January 2013 and currently serves as Chairman of our Board, Chair of our Nominating and Corporate Governance Committee, and a member of our Compensation Committee. Mr. Funari served as Chief Executive Officer and Chairman of the board of directors of Crescent Healthcare, a provider of integrated pharmacy and nursing solutions in alternate site settings, from 2004 until its acquisition by Walgreens in February 2012. Before joining Crescent Healthcare, Mr. Funari was Executive Vice President and Chief Operating Officer at Syncor International Corporation, a publicly-traded radiopharmacy services company, from 1993 to 1996 and also served as its President and Chief Executive Officer from 1996 to 2003. Mr. Funari was Executive Vice President and General Manager of the drug company for McKesson, Inc., a provider of pharmaceuticals, medical supplies and healthcare information technologies, and spent more than 18 years in a broad range of leadership positions at Baxter International Inc., a health care company. Mr. Funari served as a director of Beckman Coulter, Inc., a diagnostics and life sciences company, where he was a member of the compensation committee from 2005 to 2011 as well as a director of Pope and Talbot, Inc., a forest products company, where he was on the governance and compensation committees from 2001 to 2008. He also served as a director of First Consulting Group from 2004 to 2008 and a director of Bay Cities National Bank from 1994 to 2010 where he also served as Chairman from 2007 to 2010. He currently sits on the boards of directors of a number of non-profit and private companies and is a member of the RAND Healthcare Board of Advisors. Mr. Funari received the Ernst & Young Entrepreneur of the Year 2010 Award in the turnaround category in Orange County/Desert cities. Mr. Funari’s executive leadership, particularly in the healthcare industry, and proven track record of strategic planning and implementation uniquely qualifies him to serve on our Board. - Robert G. Funari，他自2013年1月担任NxStage的董事，目前担任本公司的董事长，以及提名和公司治理委员会主席。他自2004年担任Crescent Healthcare（在备用站点设置综合性制药和护理解决方案供应商）的首席执行官兼董事会主席，直到该公司于2012年2月被Walgreens收购。在加入Crescent Healthcare之前，1993年至1996年，他在Syncor International Corporation（一家公开上市的放射性药物服务公司）担任执行副总裁兼首席营运官，并从1996年到2003年，担任该公司的总裁兼首席执行官。他曾担任McKesson药物公司（一家药品，医疗用品和医疗信息技术提供商）的执行副总裁兼总经理，并曾在Baxter International（ 一家医疗保健公司）工作了超过18年，担任过多个领导职位。他曾是Beckman Coulter（一家诊断和生命科学公司）的董事，并从2005年至2011年12月担任其薪酬委员会的成员。他还曾是Pope and Talbot（一家林产品公司）的董事，并从2001年至2008年，担任其治理和薪酬委员会的成员。2004年至2008年，他曾担任First Consulting Group的董事。从1994年至2010年9月，他还担任过Bay Cities National Bank的董事，并从2007年到2010年9月，担任其董事长。他目前是一些非营利和私营公司的董事会成员，并且是RAND Healthcare Board of Advisors的成员。
- Robert G. Funari has been a director of NxStage since January 2013 and currently serves as Chairman of our Board, Chair of our Nominating and Corporate Governance Committee, and a member of our Compensation Committee. Mr. Funari served as Chief Executive Officer and Chairman of the board of directors of Crescent Healthcare, a provider of integrated pharmacy and nursing solutions in alternate site settings, from 2004 until its acquisition by Walgreens in February 2012. Before joining Crescent Healthcare, Mr. Funari was Executive Vice President and Chief Operating Officer at Syncor International Corporation, a publicly-traded radiopharmacy services company, from 1993 to 1996 and also served as its President and Chief Executive Officer from 1996 to 2003. Mr. Funari was Executive Vice President and General Manager of the drug company for McKesson, Inc., a provider of pharmaceuticals, medical supplies and healthcare information technologies, and spent more than 18 years in a broad range of leadership positions at Baxter International Inc., a health care company. Mr. Funari served as a director of Beckman Coulter, Inc., a diagnostics and life sciences company, where he was a member of the compensation committee from 2005 to 2011 as well as a director of Pope and Talbot, Inc., a forest products company, where he was on the governance and compensation committees from 2001 to 2008. He also served as a director of First Consulting Group from 2004 to 2008 and a director of Bay Cities National Bank from 1994 to 2010 where he also served as Chairman from 2007 to 2010. He currently sits on the boards of directors of a number of non-profit and private companies and is a member of the RAND Healthcare Board of Advisors. Mr. Funari received the Ernst & Young Entrepreneur of the Year 2010 Award in the turnaround category in Orange County/Desert cities. Mr. Funari’s executive leadership, particularly in the healthcare industry, and proven track record of strategic planning and implementation uniquely qualifies him to serve on our Board.
- Jean K. Mixer
-
Jean K. Mixer，她自2012年11月担任NxStage的董事。她自2014年1月担任Boston Children’s Hospital的战略副总裁。从2005年到2014年1月，她曾担任Mixerconsulting的首席执行官，通过战略和组织工作促进组织发展。从1992年到2004年，她在Boston Consulting Group（一家管理咨询公司）任职并担任合伙人。在此之前，她在J.P. Morgan（一家金融服务公司）担任主管。从2006年到2014年1月，她任职于Cambridge Trust Company（一家商业银行）的董事会，并担任董事会的执行委员会成员以及薪酬委员会主席。她还是Boys and Girls Clubs of Boston的监工，并担任其人力资源委员会主席。此前，她任职于National Health Care Reform的商业圆桌会议委员会（Business Round Table Committee）。
Jean K. Mixer has served as a director of NxStage since November 2012 and currently serves as a member of both our Audit and Compensation Committees. Ms. Mixer is the Vice President of Strategy and Digital Health at Boston Children’s Hospital, which she joined in January 2014. From 2005 to January 2014 she served as Chief Executive Officer of mixerconsulting, which has helped organizations grow through strategic and organizational work. From 1992 to 2004 she was at The Boston Consulting Group, a management consulting firm, where she also served as partner. Before that, Ms. Mixer was an officer at J.P. Morgan, a financial services firm. From 2006 to January 2014 Ms. Mixer was a director on the board of the Cambridge Trust Company, a commercial bank, where she also served as a member of the board’s executive committee and chair of its compensation committee. She is also an overseer at the Boys and Girls Clubs of Boston and has served as the chair of its human resources committee. Formerly, she served on the Business Roundtable Committee on National Health Care Reform. She has worked broadly across the restructuring healthcare market, including providers, payers, pharmaceuticals, medical devices and pharmacy/PBMs. - Jean K. Mixer，她自2012年11月担任NxStage的董事。她自2014年1月担任Boston Children’s Hospital的战略副总裁。从2005年到2014年1月，她曾担任Mixerconsulting的首席执行官，通过战略和组织工作促进组织发展。从1992年到2004年，她在Boston Consulting Group（一家管理咨询公司）任职并担任合伙人。在此之前，她在J.P. Morgan（一家金融服务公司）担任主管。从2006年到2014年1月，她任职于Cambridge Trust Company（一家商业银行）的董事会，并担任董事会的执行委员会成员以及薪酬委员会主席。她还是Boys and Girls Clubs of Boston的监工，并担任其人力资源委员会主席。此前，她任职于National Health Care Reform的商业圆桌会议委员会（Business Round Table Committee）。
- Jean K. Mixer has served as a director of NxStage since November 2012 and currently serves as a member of both our Audit and Compensation Committees. Ms. Mixer is the Vice President of Strategy and Digital Health at Boston Children’s Hospital, which she joined in January 2014. From 2005 to January 2014 she served as Chief Executive Officer of mixerconsulting, which has helped organizations grow through strategic and organizational work. From 1992 to 2004 she was at The Boston Consulting Group, a management consulting firm, where she also served as partner. Before that, Ms. Mixer was an officer at J.P. Morgan, a financial services firm. From 2006 to January 2014 Ms. Mixer was a director on the board of the Cambridge Trust Company, a commercial bank, where she also served as a member of the board’s executive committee and chair of its compensation committee. She is also an overseer at the Boys and Girls Clubs of Boston and has served as the chair of its human resources committee. Formerly, she served on the Business Roundtable Committee on National Health Care Reform. She has worked broadly across the restructuring healthcare market, including providers, payers, pharmaceuticals, medical devices and pharmacy/PBMs.
高管简历
中英对照 | 中文 | 英文- Jeffrey H. Burbank
Jeffrey H. Burbank，他在1998年创立了NxStage，并担任董事及首席执行官。他在公司发展，营销和为终末期肾脏疾病患者制造产品等方面拥有超过25年的的深入管理经验。自NxStage成立以来，他领导公司经历其所有的发展阶段，包括成功启动，商业活动的快速增长，首次公开募股，以及收购Medisystems Corporation。在建立NxStage之前，他联合创立了Vasca（该公司提供创新性的植入式接入设备），并担任总裁，首席执行官，以及公司董事会主席。他在Gambro（一家医疗技术公司）工作了9年，获得了重要的行业经验。他在Gambro最后的职位是营销和高级技术总监。
Jeffrey H. Burbank is Chief Executive Officer and a member of Board of Directors and has served in these positions since he founded the company in December 1998. Mr. Burbank has over 30 years of in-depth management experience with companies developing, marketing and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Mr. Burbank co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received his BS in Industrial Engineering from Lehigh University.- Jeffrey H. Burbank，他在1998年创立了NxStage，并担任董事及首席执行官。他在公司发展，营销和为终末期肾脏疾病患者制造产品等方面拥有超过25年的的深入管理经验。自NxStage成立以来，他领导公司经历其所有的发展阶段，包括成功启动，商业活动的快速增长，首次公开募股，以及收购Medisystems Corporation。在建立NxStage之前，他联合创立了Vasca（该公司提供创新性的植入式接入设备），并担任总裁，首席执行官，以及公司董事会主席。他在Gambro（一家医疗技术公司）工作了9年，获得了重要的行业经验。他在Gambro最后的职位是营销和高级技术总监。
- Jeffrey H. Burbank is Chief Executive Officer and a member of Board of Directors and has served in these positions since he founded the company in December 1998. Mr. Burbank has over 30 years of in-depth management experience with companies developing, marketing and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Mr. Burbank co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received his BS in Industrial Engineering from Lehigh University.
- Winifred L. Swan
Winifred L. Swan， 她自2005年1月担任本公司的高级副总裁兼总法律顾问。在此之前，她自2000年11月担任本公司的副总裁兼法律总顾问。她在医疗设备领域拥有超过20年的法律专业知识。在加入NxStage之前，她担任Boston Scientific Corporation（一家医疗器械公司）的资深企业法律顾问，专注于并购和业务发展交易。在此之前，她在Goodwin Procter（一家律师事务所）担任合伙人，专门从事公司法和证券法。在法学院之前，她在Merrill Lynch（一间财务管理咨询公司）的资本市场集团担任财务分析师。她在杜克大学（Duke University）获得了经济学和公共政策的学士学位，并在宾夕法尼亚大学（University of Pennsylvania）获得了法学博士学位。
Winifred L. Swan is our Senior Vice President and General Counsel and has served in these positions since January 2005. Before that, she served as our Vice President and General Counsel since November 2000. Ms. Swan has over 20 years of legal expertise in medical devices. Prior to joining NxStage, Ms. Swan was Senior Corporate Counsel at Boston Scientific Corporation, a medical device company, where she focused on mergers and acquisitions and business development transactions. Before that, she was an associate at Goodwin Procter LLP, a law firm, specializing in corporate and securities law. Prior to law school, Ms. Swan served as a financial analyst in the Capital Markets Group of Merrill Lynch, a financial management and advisory company. Ms. Swan received a BA in Economics and Public Policy from Duke University and her JD from the University of Pennsylvania.- Winifred L. Swan， 她自2005年1月担任本公司的高级副总裁兼总法律顾问。在此之前，她自2000年11月担任本公司的副总裁兼法律总顾问。她在医疗设备领域拥有超过20年的法律专业知识。在加入NxStage之前，她担任Boston Scientific Corporation（一家医疗器械公司）的资深企业法律顾问，专注于并购和业务发展交易。在此之前，她在Goodwin Procter（一家律师事务所）担任合伙人，专门从事公司法和证券法。在法学院之前，她在Merrill Lynch（一间财务管理咨询公司）的资本市场集团担任财务分析师。她在杜克大学（Duke University）获得了经济学和公共政策的学士学位，并在宾夕法尼亚大学（University of Pennsylvania）获得了法学博士学位。
- Winifred L. Swan is our Senior Vice President and General Counsel and has served in these positions since January 2005. Before that, she served as our Vice President and General Counsel since November 2000. Ms. Swan has over 20 years of legal expertise in medical devices. Prior to joining NxStage, Ms. Swan was Senior Corporate Counsel at Boston Scientific Corporation, a medical device company, where she focused on mergers and acquisitions and business development transactions. Before that, she was an associate at Goodwin Procter LLP, a law firm, specializing in corporate and securities law. Prior to law school, Ms. Swan served as a financial analyst in the Capital Markets Group of Merrill Lynch, a financial management and advisory company. Ms. Swan received a BA in Economics and Public Policy from Duke University and her JD from the University of Pennsylvania.
- Joseph E. Turk, Jr.
Joseph E. Turk, Jr.， 他自2013年11月担任本公司的总裁。在此之前，从2010年12月至2013年11月，他担任本公司北美业务总裁；从2005年1月至2010年12月，担任商业运营高级副总裁；从2000年5月至2005年1月，担任副总裁，负责销售和市场营销。他为NxStage带来了深厚的战略和市场发展的经验背景。在加入NxStage之前，他担任Boston Scientific Corporation（一家医疗器械公司）的新业务发展总监。在此之前，他是McKinsey & Company（一家管理咨询公司）的中西部医疗保健和生物技术实践的领导者之一，并担任其芝加哥办事处的高级业务经理。他在Wabash College获得了经济学学士学位，并在Northwestern University的J.L. Kellogg School获得了MBA学位（市场营销和金融方向）。
Joseph E. Turk, Jr. is our President and has served in this position since November 2013. Before that, Mr. Turk served as our President of North American Operations from December 2010 to November 2013 Senior Vice President, Commercial Operations from January 2005 to December 2010 and Vice President, Sales and Marketing from May 2000 to January 2005. Prior to joining NxStage, he served as Director of New Business Development at Boston Scientific Corporation, a medical device company. Before that, he was one of the leaders of the Midwest Health Care and Biotechnology Practice of McKinsey & Company, a management consulting firm, as a Senior Engagement Manager in the firm's Chicago office. Mr. Turk received an AB in Economics from Wabash College and his MBA in Marketing and Finance from Northwestern University's J.L. Kellogg School.- Joseph E. Turk, Jr.， 他自2013年11月担任本公司的总裁。在此之前，从2010年12月至2013年11月，他担任本公司北美业务总裁；从2005年1月至2010年12月，担任商业运营高级副总裁；从2000年5月至2005年1月，担任副总裁，负责销售和市场营销。他为NxStage带来了深厚的战略和市场发展的经验背景。在加入NxStage之前，他担任Boston Scientific Corporation（一家医疗器械公司）的新业务发展总监。在此之前，他是McKinsey & Company（一家管理咨询公司）的中西部医疗保健和生物技术实践的领导者之一，并担任其芝加哥办事处的高级业务经理。他在Wabash College获得了经济学学士学位，并在Northwestern University的J.L. Kellogg School获得了MBA学位（市场营销和金融方向）。
- Joseph E. Turk, Jr. is our President and has served in this position since November 2013. Before that, Mr. Turk served as our President of North American Operations from December 2010 to November 2013 Senior Vice President, Commercial Operations from January 2005 to December 2010 and Vice President, Sales and Marketing from May 2000 to January 2005. Prior to joining NxStage, he served as Director of New Business Development at Boston Scientific Corporation, a medical device company. Before that, he was one of the leaders of the Midwest Health Care and Biotechnology Practice of McKinsey & Company, a management consulting firm, as a Senior Engagement Manager in the firm's Chicago office. Mr. Turk received an AB in Economics from Wabash College and his MBA in Marketing and Finance from Northwestern University's J.L. Kellogg School.
- Matthew W. Towse
Matthew W. Towse， 他自2013年7月担任本公司的高级副总裁，首席财务官兼司库。他在多个行业的上市公司和私人公司拥有超过25年的全球金融管理经验。在加入NxStage之前，他自2006年担任Vette Corp.（一家风险投资支持的全球设计，工程和制造技术公司）的副总裁兼首席财务官，直到该公司于2012年4月被一个战略买家收购。从2003年到2005年，他担任Fairchild Semiconductor International的高级副总裁兼首席财务官。此前，1997年至2003年，他担任Fairchild的副总裁兼企业司库。1991年至1997年，在Fairchild从National分拆出来之前，他在National Semiconductor担任过不同的财务职位。在职业生涯早期，他在Ernst & Young（一家审计公司）担任审计经理。最近，他担任Tatum（一家行政服务机构）的临时首席财务官。他是一名注册会计师，并在University of Notre Dame获得了工商管理学士学位。
Matthew W. Towse is our Senior Vice President, Chief Financial Officer and Treasurer and has served in these positions since July 2013. He has also served as our Chief Accounting Officer since January 2015. Mr. Towse has over 25 years of experience in global financial management with both public and private companies across multiple industries. Prior to joining NxStage, he served as Vice President and Chief Financial Officer of Vette Corp., a venture-capital backed global design, engineering and manufacturing technology company from 2006 until its acquisition by a strategic buyer in April 2012. From 2003 to 2005 he served as Senior Vice President and Chief Financial Officer of Fairchild Semiconductor International, Inc. Previously, Mr. Towse served as Fairchild’s Vice President and Corporate Treasurer from 1997 to 2003 and held various financial positions with National Semiconductor from 1991 to 1997 before becoming part of the team that spunoff Fairchild from National. Earlier in his career, Mr. Towse was an audit manager with Ernst & Young LLP, an auditing firm, and most recently, he served as an Interim Chief Financial Officer with Tatum, LLC, an executive services firm. Mr. Towse is a Certified Public Accountant and received his BBA from the University of Notre Dame.- Matthew W. Towse， 他自2013年7月担任本公司的高级副总裁，首席财务官兼司库。他在多个行业的上市公司和私人公司拥有超过25年的全球金融管理经验。在加入NxStage之前，他自2006年担任Vette Corp.（一家风险投资支持的全球设计，工程和制造技术公司）的副总裁兼首席财务官，直到该公司于2012年4月被一个战略买家收购。从2003年到2005年，他担任Fairchild Semiconductor International的高级副总裁兼首席财务官。此前，1997年至2003年，他担任Fairchild的副总裁兼企业司库。1991年至1997年，在Fairchild从National分拆出来之前，他在National Semiconductor担任过不同的财务职位。在职业生涯早期，他在Ernst & Young（一家审计公司）担任审计经理。最近，他担任Tatum（一家行政服务机构）的临时首席财务官。他是一名注册会计师，并在University of Notre Dame获得了工商管理学士学位。
- Matthew W. Towse is our Senior Vice President, Chief Financial Officer and Treasurer and has served in these positions since July 2013. He has also served as our Chief Accounting Officer since January 2015. Mr. Towse has over 25 years of experience in global financial management with both public and private companies across multiple industries. Prior to joining NxStage, he served as Vice President and Chief Financial Officer of Vette Corp., a venture-capital backed global design, engineering and manufacturing technology company from 2006 until its acquisition by a strategic buyer in April 2012. From 2003 to 2005 he served as Senior Vice President and Chief Financial Officer of Fairchild Semiconductor International, Inc. Previously, Mr. Towse served as Fairchild’s Vice President and Corporate Treasurer from 1997 to 2003 and held various financial positions with National Semiconductor from 1991 to 1997 before becoming part of the team that spunoff Fairchild from National. Earlier in his career, Mr. Towse was an audit manager with Ernst & Young LLP, an auditing firm, and most recently, he served as an Interim Chief Financial Officer with Tatum, LLC, an executive services firm. Mr. Towse is a Certified Public Accountant and received his BBA from the University of Notre Dame.